Literature DB >> 15822109

Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.

Joseph Jankovic1.   

Abstract

Fluctuations in the symptoms of Parkinson's disease (PD), such as wearing-off and on-off effects, and dyskinesias are related to a variety of factors, including duration and dosage of levodopa, age at onset, stress, sleep, food intake, and other pharmacokinetic and pharmacodynamic mechanisms. The majority of patients, particularly those with young onset of PD, experience these levodopa-related adverse effects after a few years of treatment. Assessment of these motor complications is difficult because of the marked clinical variability between and within patients. Daily diaries have been used in clinical trials designed to assess the effects of various pharmacological and surgical interventions on motor fluctuations and dyskinesias. The most common type of dyskinesia, called "peak-dose dyskinesia", usually consists of stereotypical choreic or ballistic movements involving the head, trunk, and limbs, and occasionally, the respiratory muscles, whereas tremor and punding are less-common complications. Dystonia is also typically seen in patients with diphasic dyskinesia and wearing-off effect. Recognition of the full spectrum of clinical phenomenology of levodopa-related motor complications is essential for their treatment and prevention. (c) 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15822109     DOI: 10.1002/mds.20458

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  126 in total

1.  Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

Authors:  Corinne Y Ostock; Kristin B Dupre; Karen L Eskow Jaunarajs; Hannah Walters; Jessica George; David Krolewski; Paul D Walker; Christopher Bishop
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

2.  Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Authors:  Manfred Gerlach; Jürgen Beck; Peter Riederer; Maarten van den Buuse
Journal:  J Neural Transm (Vienna)       Date:  2011-01-28       Impact factor: 3.575

3.  Mechanisms underlying and medical management of L-Dopa-associated motor complications.

Authors:  Manfred Gerlach; Peter Riederer; Dieter Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-12       Impact factor: 3.575

Review 4.  Soluble and controlled-release preparations of levodopa: do we really need them?

Authors:  Giovanni Fabbrini; Flavio Di Stasio; Maria Bloise; Alfredo Berardelli
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

5.  Management of punding in Parkinson's disease: an open-label prospective study.

Authors:  A Fasano; L Ricciardi; M Pettorruso; A R Bentivoglio
Journal:  J Neurol       Date:  2010-11-12       Impact factor: 4.849

Review 6.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 7.  The many facets of motor learning and their relevance for Parkinson's disease.

Authors:  Lucio Marinelli; Angelo Quartarone; Mark Hallett; Giuseppe Frazzitta; Maria Felice Ghilardi
Journal:  Clin Neurophysiol       Date:  2017-04-09       Impact factor: 3.708

Review 8.  Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.

Authors:  Annalisa Pinna; Marcello Serra; Micaela Morelli; Nicola Simola
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

9.  Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.

Authors:  Elissa M Strome; Athanasios P Zis; Doris J Doudet
Journal:  J Psychiatry Neurosci       Date:  2007-05       Impact factor: 6.186

Review 10.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.